**Supplementary Table 1.** Unadjusted analyses of disease activity and patient-reported outcome measures in patients with psoriasis in CTT areas vs patients without CTT areas at time of registry enrollment

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcome Measure** | **All Patients**  **N = 2042** | **Scalp Psoriasis**  **n = 778** | **No Scalp Psoriasis**  **n = 1264** | **Nail Psoriasis**  **n = 326** | **No Nail Psoriasis**  **n = 1716** | **Palmoplantar Psoriasis**  **n = 223** | **No Palmoplantar**  **Psoriasis**  **n = 1819** |
| IGA (0-4) | n = 2040 | n = 778 | n = 1262 | n = 326 | n = 1714 | n = 223 | n = 1817 |
| Mean (SD) | 2.9 (0.8) | 3.0 (0.8)a | 2.9 (0.8) | 2.9 (0.9) | 2.9 (0.8) | 3.0 (0.8) | 2.9 (0.8) |
| IGA categories, n (%) |  |  |  |  |  |  |  |
| 0: Clear | 44 (2.2) | 19 (2.4)b | 25 (2.0) | 13 (4.0) | 31 (1.8) | 3 (1.3) | 41 (2.3) |
| 1: Almost clear | 64 (3.1) | 20 (2.6)b | 44 (3.5) | 8 (2.5) | 56 (3.3) | 4 (1.8) | 60 (3.3) |
| 2: Mild | 342 (16.8) | 108 (13.9)b | 234 (18.5) | 49 (15.0) | 293 (17.1) | 37 (16.6) | 305 (16.8) |
| 3: Moderate | 1197 (58.7) | 455 (58.5)b | 742 (58.8) | 181 (55.5) | 1016 (59.3) | 126 (56.5) | 1071 (58.9) |
| 4: Severe | 393 (19.3) | 176 (22.6)b | 217 (17.2) | 75 (23.0) | 318 (18.6) | 53 (23.8) | 340 (18.7) |
| BSA (% involvement) | n = 2039 | n = 778 | n = 1261 | n = 326 | n = 1713 | n = 223 | n = 1816 |
| Mean (SD) | 15.6 (16.6) | 17.0 (17.8)a | 14.7 (15.8) | 18.4 (20.0)a | 15.1 (15.9) | 15.0 (17.8) | 15.7 (16.5) |
| BSA categories, n (%) |  |  |  |  |  |  |  |
| Mild (< 3%) | 218 (10.7) | 76 (9.8) | 142 (11.3) | 40 (12.3) | 178 (10.4)b | 31 (13.9) | 187 (10.3) |
| Moderate (3%-10%) | 922 (45.2) | 336 (43.2) | 586 (46.5) | 124 (38.0) | 798 (46.6)b | 107 (48.0) | 815 (44.9) |
| Severe (> 10%) | 899 (44.1) | 366 (47.0) | 533 (42.3) | 162 (49.7) | 737 (43.0)b | 85 (38.1) | 814 (44.8) |
| PASI score (0-72) | n = 2041 | n = 778 | n = 1263 | n = 326 | n = 1715 | n = 223 | n = 1818 |
| Mean (SD) | 9.1 (8.1) | 10.3 (9.4)a | 8.4 (7.1) | 11.9 (10.9)a | 8.6 (7.4) | 9.9 (9.7) | 9.1 (7.9) |
| PASI > 10, n (%) | 696 (34.1) | 306 (39.3)a | 390 (30.9) | 144 (44.2)a | 552 (32.2) | 79 (35.4) | 617 (33.9) |
| Patient pain (VAS 0-100) | n = 2039 | n = 775 | n = 1264 | n = 325 | n = 1714 | n = 223 | n = 1816 |
| Mean (SD) | 36.5 (33.3) | 37.8 (33.0) | 35.7 (33.4) | 40.7 (34.4)a | 35.7 (33.0) | 46.4 (33.9)a | 35.3 (33.0) |
| Patient fatigue (VAS 0-100) | n = 2036 | n = 774 | n = 1262 | n = 325 | n = 1711 | n = 223 | n = 1813 |
| Mean (SD) | 37.7 (29.9) | 39.1 (29.5) | 36.9 (30.1) | 41.1 (29.2)a | 37.1 (29.9) | 42.8 (29.1)a | 37.1 (29.9) |
| Patient itch (VAS 0-100) | n = 2039 | n = 778 | n = 1261 | n = 325 | n = 1716 | n = 223 | n = 1818 |
| Mean (SD) | 55.6 (33.5) | 58.7 (32.3)a | 53.7 (34.1) | 57.6 (32.9) | 55.2 (33.6) | 61.4 (31.3)a | 54.9 (33.7) |
| EQ VAS (0-100) | n = 2037 | n = 776 | n = 1261 | n = 325 | n = 1712 | n = 223 | n = 1814 |
| Mean (SD) | 69.1 (22.6) | 67.7 (23.3)a | 70.0 (22.2) | 65.4 (23.9)a | 69.8 (22.3) | 64.6 (24.4)a | 69.7 (22.4) |
| DLQI (0-30) | n = 2039 | n = 775 | n = 1264 | n = 326 | n = 1713 | n = 223 | n = 1816 |
| Mean (SD) | 8.9 (6.2) | 9.1 (6.2) | 8.8 (6.1) | 9.4 (6.5) | 8.8 (6.1) | 10.6 (6.2)a | 8.7 (6.1) |
| Effect on life, n (%) |  |  |  |  |  |  |  |
| None (0-1) | 187 (9.2) | 64 (8.3) | 123 (9.7) | 38 (11.7) | 149 (8.7) | 8 (3.6)b | 179 (9.9) |
| Small (2-5) | 538 (26.4) | 205 (26.5) | 333 (26.3) | 68 (20.9) | 470 (27.4) | 44 (19.7)b | 494 (27.2) |
| Moderate (6-10) | 573 (28.1) | 215 (27.7) | 358 (28.3) | 94 (28.8) | 479 (28.0) | 67 (30.0)b | 506 (27.9) |
| Very large (11-20) | 629 (30.8) | 247 (31.9) | 382 (30.2) | 103 (31.6) | 526 (30.7) | 83 (37.2)b | 546 (30.1) |
| Extremely large (21-30) | 112 (5.5) | 44 (5.7) | 68 (5.4) | 23 (7.1) | 89 (5.2) | 21 (9.4)b | 91 (5.0) |
| Currently employed, n (%) | n = 2038 1382 (67.8) | n = 777 537 (69.1) | n = 1261 845 (67.0) | n = 326  220 (67.5) | n = 1712  1162 (67.9) | n = 223  141 (63.2) | n = 1815  1241 (68.4) |
| WPAI domains |  |  |  |  |  |  |  |
| Absenteeism (work time missed), % | n = 1226 | n = 477 | n = 749 | n = 202 | n = 1024 | n = 123 | n = 1103 |
| Mean (SD) | 4.1 (13.5) | 4.4 (13.1) | 3.9 (13.7) | 3.9 (13.4) | 4.1 (13.5) | 4.8 (12.4) | 4.0 (13.6) |
| Presenteeism (impairment at work/reduced on-the-job effectiveness), % | n = 1221 | n = 477 | n = 744 | n = 200 | n = 1021 | n = 123 | n = 1098 |
| Mean (SD) | 17.6 (23.9) | 18.8 (24.2) | 16.7 (23.6) | 17.4 (23.5) | 17.6 (24.0) | 23.5 (26.7)a | 16.9 (23.5) |
| Work productivity loss (overall work impairment/absenteeism plus presenteeism), % | n = 1213 | n = 473 | n = 740 | n = 199 | n = 1014 | n = 123 | n = 1090 |
| Mean (SD) | 19.2 (25.2) | 21.0 (25.7) | 18.1 (24.8) | 18.9 (24.5) | 19.3 (25.3) | 25.8 (27.9)a | 18.5 (24.8) |
| Activity impairment, % | n = 2015 | n = 763 | n = 1252 | n = 320 | n = 1695 | n = 217 | n = 1798 |
| Mean (SD) | 24.9 (28.7) | 25.4 (28.2) | 24.7 (29.0) | 26.7 (28.8) | 24.6 (28.6) | 35.9 (30.9)a | 23.6 (28.1) |

BSA, body surface area; CTT, challenging-to-treat; DLQI, Dermatology Life Quality Index; EQ VAS, EuroQol visual analogue scale; IGA, Investigator’s Global Assessment; PASI, Psoriasis Area and Severity Index; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment.

a *P* < .05 for the comparison between patients with vs those without the condition.

b *P* < .05 for the overall distribution across categories of patients with vs those without the condition.